The United States approved the drug for the treatment of Prader-Villy's syndrome

Management that controls the products and medicines approved the use of the drug for the treatment of Prader-Villy syndrome. The tool has been developed by Soleno Therapeutics.

The drug received the trade name Vykat XR, writes Xrust. They will be treated with hyperphagia or prader-villi syndrome. This is a genetic disease caused by a complete or partial deed on chromosome 15. It affects the regulation of genes expression, or how the genes are turned on and off.

The disease is serious. 50,000 people suffer from him in the USA. It manifests itself in everyday life at a meal and mood. Since the upcoming April, the Soleno developer plans to make the drug available in the United States for patients aged four years and older. The average annual budget of the drug will exceed $ 466 thousand.

Symptoms of the syndrome appear immediately. Infants are born with low muscle tone and inability to breastfeeding. As they grow older in children, hyperphagia develops — a feeling of insatiable hunger, which persists even after eating.